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wards luminal differentiation. Conclusions: The switch 
towards luminal phenotype suggests some kind of endo-
crine effect of NAC. Our findings raise renewed interest 
in combinatorial cytotoxic chemotherapy with concomi-
tant or rather sequential endocrine therapy, either alone 
or with targeted agents.
© 2017 S. Karger GmbH, Freiburg
Introduction
Neoadjuvant chemotherapy (NAC) was originally introduced to 
reduce tumor size and enable surgery of locally advanced breast can-
cer (BC) [1]. Subsequent meta-analyses showed no differences in 
outcome between pre- and post-operative chemotherapy [2]. More 
recently, NAC has been considered as a unique opportunity to un-
derstand BC biology, thanks to the possibility of analyzing paired 
tumor samples before and after treatment [3]. The agents developed 
in this setting are similar to those validated in the adjuvant context, 
anthracyclines and taxanes being the most effective compounds [4]. 
Previous studies investigated the relation between Ki-67 drop and 
response to NAC. More recently, scientific interest was raised by the 
effects of NAC on hormone receptor (HR) and HER2 expression. 
Nevertheless, most previous works focused on small populations 
and various cytotoxic regimens. The objective of this study was to 
address BC phenotype changes in a homogeneous population of pa-
tients with localized or metastatic disease, mostly treated with an-
thracycline and taxane-based NAC within the same institution.
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Summary
Background: Breast cancer (BC) phenotype after neoad-
juvant chemotherapy (NAC) has not been extensively de-
scribed and few data exist on whether expression of the 
primary tumor hormone receptors, HER2 and Ki-67 
changes as a result of chemotherapy. Materials and 
Methods: We analyzed specimens from all BC patients 
treated with anthracycline/taxane-based NAC at our In-
stitution between January 2010 and March 2015 
(n = 325). The expression of estrogen receptor (ER), pro-
gesterone receptor (PR), HER2 and Ki-67 was determined 
in pre- and post-NAC specimens. McNemar’s test was 
used to compare paired proportions. Results: Among pa-
tients with residual disease after NAC, basal phenotype 
was luminal A, luminal B, HER2 positive and triple nega-
tive in 44, 111, 74 and 27 cases, respectively. PR-positive 
tumors decreased from 68.0% in the initial biopsy sam-
ple to 61.7% in the surgical specimen (p = 0.024). A Ki-67 
of < 20% increased from 23.6% to 45% (p < 0.001). ER 
expression changed from positive to negative in 5% and 
from negative to positive in 16.7% of cases. Overall, 30% 
of cases underwent subtype changes, 79% of them to-
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Materials and Methods
We retrospectively collected information from the institutional database on 
all consecutive BC patients treated with NAC who underwent surgery at the Is-
tituto Nazionale dei Tumori, Milan, Italy, between 1 January 2010 and 31 
March 2015. For the current analysis we excluded all cases treated with chemo-
therapy in our Institution but undergoing surgery in other Institutions, as well 
as those without paired basal and surgical histological specimens and/or those 
treated with experimental therapy within a clinical trial. Data about patients’ 
age, NAC regimen and duration, type and timing of surgery, clinical and patho-
logical BC stage, and disease phenotype before and after NAC were extracted. 
All cases obtaining pathological complete response (pCR) were excluded from 
analysis. In absence of contraindications, all patients received anthracycline and 
taxane-based NAC. All HER2-positive cases were treated with trastuzumab, ac-
cording to international guidelines. HR and HER2 status, Ki-67 index and dis-
ease stage were examined by Institutional pathologists. Diagnostic cut-offs for 
HR and HER2 positivity were defined according to American Society of Clini-
cal Oncology–College of American Pathologists (ASCO-CAP) guidelines [5, 6]. 
Tumor subtype classification followed the St. Gallen/Vienna 2015 criteria [7]. 
All surgical specimens were completely sampled to detect residual disease. pCR 
was defined as the absence of invasive disease in both breast and lymph nodes. 
The primary objective of the study was to estimate percentage of changes in HR 
and HER2 status after NAC. Secondary objective was to compare percentage of 
cases with a specific tumor receptor status between pre- and post-NAC setting. 
2-sided 95% exact confidence intervals (CIs) were calculated to estimate per-
centage of patients changing BC subtype. The 2-sided exact McNemar’s test was 
used to assess equality of basal and surgical paired percentages. Patients’ and 
tumor characteristics, NAC regimens and disease response were summarized 
using descriptive statistics (median and range for continuous variables, absolute 
and percentage frequencies for categorical ones). Median follow-up was esti-
mated using the reverse Kaplan-Meier method. Given the descriptive nature of 
the study, a quantitative hypothesis testing was applied instead that a formal 
one (e.g. no thresholds for statistical significance were defined). Statistical anal-
ysis was performed using SAS software, version 9.2 (SAS Institute, Cary, NC, 
USA).
Results
We identified 325 case with a median age of 51  years (range 
23–85 years). Details about patients’ and tumor characteristics are 
summarized in table 1 and table 2. 31 patients achieved pCR and 
were therefore excluded from analysis. Among the 294 patients 
with residual disease at surgery, paired tissue samples for determi-
nation estrogen receptor (ER) status at diagnostic biopsy and sur-
gery were available in 274 cases (93.2%). 11 of 220 (5.0%, CI 2.5–
8.8%) patients showed a change from ER-positive to ER-negative 
disease. 9 of 54 (16.7%, CI 7.9–29.3) patients converted from ER-
negative to ER-positive disease. 34 of 183 (18.6%, CI 13.2–25.0%) 
cases with progesterone receptor (PR)-positive primary tumor had 
PR-negative residual disease at surgery. 17 of 86 (19.8%, CI 12.0–
29.8%) cases with PR-negative disease showed PR-positivity at sur-
gery. Among the 239 patients tested for HER2 in initial biopsy and 
surgical specimen, HER2 changed from positive to negative in 9 of 
49 (18.4%, CI 8.8–32.0%) patients and from negative to positive in 
7 of 190 (3.7%, CI 1.5–7.4%). Among the 229 cases with paired val-
ues of Ki-67, its expression decreased from ˰ 20% to < 20% in 63 of 
175 (36.0%, CI 28.9–43.6%) patients and increased from < 20% to 
˰ 20% in 14 of 54 (25.9%, CI 15.0–39.7%). The expression of PR 
and Ki-67 significantly differed between basal and surgical sam-
ples. Indeed, PR positivity was reported in 68.0% (CI 62.1–73.6%) 
of diagnostic biopsy samples and in 61.7% (CI 55.6–67.5%) of sur-
gical specimens (McNemar’s test p = 0.024). Ki-67 was ˰ 20% in 
76.4% (CI 70.4–81.8%) of pre-treatment biopsies and in 55.0% (CI 
48.3–61.6%) of residual diseases (McNemar’s test p < 0.001). Over-
all, 62 of 206 (30.1%) cases presented a phenotype modification 
from basal biopsy to surgical specimen. In particular, of these 206 
Age at surgery, years 
Median  50.5
Range  22.7–84.5
ER status at diagnosis, n (%) 
Positive 239 (74.0)
Negative  84 (26.0)
Missing   2 (0.6)
PR status at diagnosis, n (%) 
Positive 198 (62.3)
Negative 120 (37.7)
Missing   7 (2.2)
HER2 status at diagnosis, n (%) 
Positive  90 (28.6)
Negative 225 (71.4)
Missing  10 (3.1)
Ki-67 status at diagnosis, n (%)
≥20% 228 (79.7)
<20%  58 (20.3)
Missing  39 (12.0)
Tumor stage at diagnosis, n (%) 
X   1 (0.3)
T1   5 (1.5)
T2 184 (56.6)
T3  31 (9.5)
T4 104 (32.0)
Nodal stage at diagnosis, n (%)
N0  95 (29.2)
N1 199 (61.2)
N2  22 (6.8)
Metastasis at diagnosis, n (%)
M0 285 (87.7)
M1  40 (12.3)
ER = estrogen receptor, PR = progesterone receptor.
Table 1. Patients’ 
characteristics
Cytotoxic regimen, n (%) 
Anthracycline and taxane 292 (91.0)
Anthracycline alone   9 (2.8)
Taxane alone  12 (3.7)
Other   8 (2.5)
Missing   4 (1.2)
Cycles administered
Median, n   6
Range, n   2–18
Missing, n (%)   9 (2.8)
Type of surgery, n (%)
Modified radical mastectomy 221 (68.0)
Conservative surgery 104 (32.0)
Table 2. Treatment 
characteristics
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patients, 24 were triple-negative (11.7%) at baseline and 30 (14.6%) 
after NAC (McNemar’s test p  =  0.070); 48 were HER2 positive 
(23.3%) at baseline and 46 (22.3%) after NAC (McNemar’s test 
p = 0.790); 40 were luminal A (19.4%) at baseline and 68 (33.0%) 
after NAC (McNemar’s test p < 0.0001); and 94 luminal B (45.6%) 
at baseline and 62 (30.1%) after NAC (McNemar’s test p < 0.0001). 
Most cases showing any kind of phenotype change presented lo-
cally advanced or metastatic disease as, of the 62, 30 (48.4%) were 
pT3-pT4, 49 (79.0%) were pN+ and 11 (17.7%) presented synchro-
nous distant metastases. Tumor marker and phenotype changes in 
paired samples are reported in table 3 and table 4.
Discussion
Change in HR and HER2 status after NAC is a well-known phe-
nomenon in BC, occurring in 10–30% of cases [8, 9]. Although the 
older results might be affected by pre-analytical and analytical pit-
falls [10, 11], a real biological heterogeneity may be implied. It was 
hypothesized that paired samples from a single lesion may differ, 
even in absence of therapeutic interventions, as a consequence of 
malignant subpopulations coexistence. Some studies supported 
this theory, identifying no differences in phenotype change rates 
between paired samples from treatment-naïve and chemo-treated 
patients [12, 13]. An alternative hypothesis supports a drug-in-
duced selection pressure towards malignant cells. Cytotoxic, endo-
crine and biological agents may specifically target and kill sensitive 
BC subpopulations, leaving behind the resistant ones. This hypoth-
esis was sustained by some studies, showing higher frequency of 
BC phenotype change in NAC-treated patients than in naïve con-
trols [14, 15]. The present work shows that most cases undergoing 
phenotype changes presented with advanced stage (pT3–4, pN+, 
cM+). This observation is in favor of the hypothesis that treatment 
might possibly affect part of a rather heterogeneous disease, lead-
ing to the emergence of an unresponsive residue. On the other 
hand, a considerable amount of data suggests that Ki-67 drop after 
NAC may be an independent positive prognostic factor in patients 
not achieving pCR [16, 17]. In the present study, we observed a 
significant decrease in PR and Ki-67 expression after NAC. This 
finding seems to support a prognostic, rather than an incidental 
role of BC phenotype change during NAC. Previous works postu-
lated that cytotoxic agents may play an endocrine role, suppressing 
ovarian and adrenal function with consequent alteration of BC bio-
logical profile [18]. Indeed, it was shown that pre-menopausal 
Initial biopsy Final surgery, n Prevalence, % (95%CI) p-value
positive  
(≥20%)
negative 
(<20%)
initial biopsy final surgery 
ER status
Positive 209  11 80.3 (75.1–84.8) 79.6 (74.3–84.2) 0.824
Negative   9  45 19.7 (15.2–24.9) 20.4 (15.6–25.7)
PR status
Positive 149  34 68.0 (62.1–73.6) 61.7 (55.6–67.5) 0.024
Negative  17  69 32.0 (26.4–37.9) 38.3 (32.5–44.4)
HER2 status
Positive  40   9 20.5 (15.6–26.2) 19.7 (14.8–25.3) 0.804
Negative   7 183 79.5 (73.8–84.4) 80.3 (74.7–85.3)
Ki-67
≥ 20% 112  63 76.4 (70.4–81.8) 55.0 (48.3–61.6) < 0.001
< 20%  14  40 23.6 (18.2–29.6) 45.0 (38.4–51.7)
Table 3. Immunohistochemistry in initial biopsy 
and surgical specimens
Basal histotype, n Post-treatment histotype, n (%)
unchanged changed missing data
Triple negative  27 23 (95.8) luminal B  1 (4.2)  3 (11.1)
triple negative  2 (4.2) 26 (35.1)
HER2 positive  74 40 (83.3) luminal A  4 (8.3)
luminal B*  2 (4.2)
Luminal A  44 31 (77.5) luminal B  9 (22.5)  4 (9.1)
Luminal B 111 50 (53.2) triple negative  5 (5.3) 17 (15.3)
HER2 positive  6 (6.4)
luminal A 33 (35.1)
*2/2 cases changed from HER2-positive to luminal B HER2-positive (triple positive) breast cancer.
Table 4. Subtype changes after NAC
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women with HR-positive tumors attaining amenorrhea after NAC 
had better outcome than menstruating women [19]. Post-meno-
pausal patients may also achieve benefit, due to adrenal endocrine 
suppression induced by cytotoxic agents [20]. If confirmed, these 
hypotheses may entail important clinical implications, as PR de-
crease may be viewed as a marker of reduced endocrine stimula-
tion in BC. Another finding of this study concerns the tendency 
towards luminal differentiation observed after NAC. Even though 
our data do not allow prognostic or pathogenetic conclusions to be 
drawn, this previously unreported finding is in line with the hy-
pothesis of an endocrine effect of chemotherapy. This observation 
potentially raises new interest in the development of sequential cy-
totoxic and hormonal NAC approaches, or combinations with in-
novative drugs such as cyclin kinase inhibitors, to target biological 
modifications of tumor phenotype induced by standard NAC. A 
plethora of gene expression profiles have been generated during 
the last decades to discover, develop and validate prognostic and 
predictive gene signatures. Some of these signatures are commer-
cially available to define the residual risk in ER-positive and HER2-
negative tumors after receiving adjuvant endocrine treatment 
(Mammaprint, Oncotype DX, Breast Cancer Index, PAM50, Endo-
Predict) [21]. Unfortunately, none of these signatures were aimed 
at specifically defining the residual risk after standard NAC. Our 
findings obtained using the St. Gallen criteria for BC classification 
suggest that gene expression profiling of residual disease could 
help to further characterize the modifications induced by anthracy-
cline/taxane NAC, with the final goal of defining patients at high 
recurrence risk despite standard treatment, who could be ideal can-
didates for trials with investigational drugs in early breast cancer. A 
significant value of our study consists in the focus on a homogene-
ous population, treated over a limited period of time. Furthermore, 
the cytotoxic and biological agents administered were in agreement 
with recent guidelines on NAC. However, some limitations of this 
work have to be underlined. First of all, it represents a retrospective 
case series based on a limited number of patients. Secondly, imma-
ture follow-up does not allow outcome conclusions to be drawn. 
Finally, this study was conceived as an explorative analysis without 
pre-defined postulates, with a speculative and hypothesis-generat-
ing aim.
In conclusion, the reported data suggest that NAC may induce 
distinct phenotypical changes in BC. We believe this observation 
deserves further evaluation as it may entail crucial implications in 
the development of new neoadjuvant therapeutic strategies.
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